Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Amphastar
Pharma
Lilly pawns off low blood sugar rescue med for $500M-plus
Eli Lilly is bidding adieu to Baqsimi, its nasal powder rescue treatment for severe hypoglycemia, or very low blood sugar, in diabetes patients.
Fraiser Kansteiner
Apr 24, 2023 9:03am
Hospira must wait to launch generic Lexiscan—but only two weeks
Sep 26, 2022 2:11pm
Momenta, Sandoz to fork over $60M in Lovenox settlement
Jun 19, 2019 12:17pm
Momenta, Sandoz fall short in $900M patent case against Amphastar
Jul 24, 2017 10:21am
Sodium bicarbonate one of 8 Pfizer drugs in short supply
May 22, 2017 10:14am
SEC targets biopharma tipster, hedge funders in insider trading suit
Jun 16, 2016 9:02am
